Clinical laboratory groups plan to focus their comments on FDA’s proposed regulatory framework for laboratory developed tests on the barriers to test access they say the new scheme will create.
Representatives of some lab groups indicated recently that they have already started to address FDA’s concerns about the clinical validity...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?